Trancriptomic characterization of labetuzumab effect on IL13-treated human bronchial epithelial cells

We have characterized the effect of the CEACAM5 targeting monoclonal antibody labetuzumab (2 µg/mL) on the transcriptional response to interleukin-13 (IL-13) treatment (10ng/mL) of air-liquid interface (ALI) cultures generated from primary human bronchial epithelial cells. ALI cultures were treated with IL-13 and labetuzumab during the last 7 days of ALI development and the transcriptomes analyzed by RNA-seq. Overall design: We analyzed the transcriptomes of 12 ALI cultures divided in 3 experimental groups: untreated control ALIs ( no IL-13, no labetuzumab), IL-13 treated ALIs and ALIs treated with both IL-13 and labetuzumab.